目的：在此回顧性研究中，我們評估食道癌接受術前同步放射與化療的治療結果，以及術後病理腫瘤減少程度與淋巴節是否有侵犯對總體存活的影響。
材料與方法：
以回溯性的方法，從 1999 年 6 月至 2011 年 4 月，64 位食道癌的病人接受術前同步放射與化療
的治療，對術後病理腫瘤減少程度、淋巴節是否有侵犯、病理分期、復發的模式與整體存活加以記錄和分析，以 Kaplan-Meier 方法計算無病和總體存活率，用 log-rank test 去作組別間的比較。Cox 迴歸分析來檢查多變數的影響。
結果：中位存活為 24.2 個月（範圍從 3-92 個月），比較術後病理腫瘤減少程度 1（TRG 1）與TRG 2-4 總體存活率（OS）沒有差異（P= 0.549），當 TRG 1-2 與 TRG 3-4 比較總體存活率（OS）有差異的趨勢（P= 0.089）。術後病理顯示沒有淋巴節侵犯與有淋巴節侵犯的中位存活分別為23.6 及 13.5 個月（P< 0.001）。在單變數分析中淋巴節侵犯（P< 0.001）與血管侵犯（P=0.041）會影響總體存活率。有淋巴節侵犯較易遠端轉移（P= 0.001），TRG 3-4 則較易局部復發（P= 0.008）。在多變數分析中只有淋巴節侵犯有意義的影響總體存活率（P= 0.004），血管侵犯（P= 0.658）則沒有相關。
結論：對於接受術前同步放射與化療治療的病人，術後病理顯示沒有殘存的淋巴節侵犯是重要的預後因子。術後病理腫瘤減少程度較不能作為預後的因子。

Purpose : In this retrospective study, we evaluated the treatment outcome following neoadjuvant chemoradiotherapy for esophageal cancer and the impact of tumor regression and post operative nodal status.
Materials and Methods : Sixty-four patients of esophageal cancer treated with neoadjuvant chemoradiotherapy from June, 1999 to April, 2011 were followed retrospectively.Tumor regression grade (TRG), post operative nodal status, pathologic stage, pattern of recurrence and overall survival (OS) of these patients were recorded and analyzed.Disease-free and overall survival rates were calculated with Kaplan-Meier method and group comparisons were based on the log-rank test. Cox regression analysis was the method applied when several factors were assessed simultaneously.
Results : Median survival is 24.2 months (range, 3-92 months). Comparing TRG 1 with TRG 2-4, the OS was not significantly different (P= 0.549). When TRG1-2 was compared with TRG3-4, there was a trend of significant difference in OS (P= 0.089).
The median survival was 23.6 months in the N– group, compared with 13.5 months in the N+ group (P< 0.001). In univariate survival analysis, N+ (P< 0.001) and vascular involvement (P= 0.041) significantly influence survival probabilities. N+ was significantly (P= 0.001) associated with distant metastasis and TRG 3-4 (P= 0.008) with locoregional recurrence. By multivariate analysis, only N+ significantly influence OS (P= 0.004) and vascular involvement (P= 0.658) was not significant.
Conclusion : For those who are receiving neoadjuvant chemoradiotherapy, achieving node-negative status is a significant prognostic factor for the outcome. As for histomorphologic tumor regression, it has a less predictive factor.